Tudriqev's Full Approval Still Hinges on an Ongoing Phase 3 Trial

Introduction

Replimune's Tudriqev (vusolimogene oderparepvec-wtpg) has reached the U.S. market after receiving accelerated approval from the Food and Drug Administration (FDA), but its regulatory journey is not yet complete.

The FDA approved Tudriqev on August 6, 2026, in combination with nivolumab (Opdivo) for adults with unresectable advanced cutaneous melanoma whose disease has progressed following an anti-PD-1-based regimen. However, because the approval was granted through the accelerated approval pathway, continued approval depends on confirming the treatment's clinical benefit in additional research.

That makes Replimune's ongoing Phase 3 IGNYTE-3 trial one of the most important next steps for the company and the future of Tudriqev.

Accelerated Approval Is Not the Final Regulatory Destination

Accelerated approval allows the FDA to make certain therapies available sooner when they address serious diseases and demonstrate evidence that is considered reasonably likely to predict clinical benefit.

For Tudriqev, the FDA's approval was based on objective response rate and duration of response from the IGNYTE study. The agency specifically states that continued approval may be contingent on verification of clinical benefit through confirmatory trial results.

This means Tudriqev can now be prescribed for its approved indication, but Replimune still has to demonstrate that the treatment's benefits are confirmed through a more rigorous clinical evaluation.

What the Phase 3 IGNYTE-3 Trial Is Designed to Do

The confirmatory study, IGNYTE-3 (NCT06264180), is evaluating Tudriqev in combination with nivolumab in patients with advanced melanoma that has progressed after previous immunotherapy.

Unlike the earlier registrational IGNYTE study, the Phase 3 trial is designed as a confirmatory comparative study, giving regulators stronger evidence for assessing the treatment's clinical benefit. The trial is specifically intended to address the questions that remained around the earlier evidence and provide the data needed to support continued approval.

The study therefore represents a critical test of whether the promising results that supported accelerated approval translate into a confirmed clinical advantage.

Why the Earlier IGNYTE Study Was Not Enough

The accelerated approval was supported by the Phase 1/2 IGNYTE study, which included 140 patients in the anti-PD-1-failed melanoma registrational cohort.

Among the 91 patients with at least one non-injected lesion who were included in the efficacy-evaluable population, Tudriqev plus nivolumab produced an objective response rate of 24.2%, with a median duration of response of 14.1 months.

These results provided the clinical signal necessary for accelerated approval. However, the study was open-label and single-arm, meaning it did not have a randomized control group.

That design became one of the central issues during Tudriqev's regulatory review.

The Challenge of Separating Tudriqev's Effect

Because patients in the registrational cohort received Tudriqev together with nivolumab, regulators faced an important scientific question: How much of the observed benefit can be attributed specifically to Tudriqev?

Without a randomized comparator group, it is more difficult to distinguish the treatment's effect from other factors.

This concern contributed to the FDA's earlier rejections of the therapy. After two previous complete response letters, Replimune submitted the application for a third review. An FDA advisory committee subsequently voted 10–3 that the IGNYTE efficacy results were evaluable and clinically meaningful, helping pave the way for the eventual accelerated approval.

The Phase 3 trial is therefore particularly important because it is expected to provide the stronger comparative evidence that was missing from the earlier study.

A Critical Test for Tudriqev's Long-Term Future

The outcome of IGNYTE-3 could determine whether Tudriqev progresses from an accelerated approval to a more firmly established regulatory position.

If the Phase 3 study verifies clinical benefit, it would strengthen the case for maintaining the indication and could provide physicians, insurers, and patients with greater confidence in the therapy.

If the study fails to confirm the expected benefit, however, Replimune could face additional regulatory challenges. Accelerated approval is specifically structured around the requirement that post-approval evidence ultimately verify the benefit supporting the initial authorization.

The trial is therefore not simply another study in Tudriqev's development program—it is central to the drug's long-term regulatory status.

Commercial Stakes Are Also High

The Phase 3 results will matter commercially as well as regulatorily.

Replimune has set Tudriqev's U.S. list price at approximately $450,000 per treatment course, making the demonstration of meaningful and durable clinical value particularly important for payers and healthcare providers.

The company is now transitioning from a development-stage biotechnology business to a commercial oncology company. Successful confirmation of Tudriqev's benefit could support broader physician adoption and strengthen the company's position in the treatment-resistant melanoma market.

Conversely, disappointing Phase 3 results could create significant commercial and financial pressure.

Tudriqev Enters a Market With Significant Unmet Need

The stakes are particularly high because Tudriqev is being used in a patient population with limited treatment options.

Patients whose melanoma progresses following anti-PD-1 therapy can face poor outcomes and few effective alternatives. Replimune's therapy offers a different approach by using a genetically modified herpes simplex virus that is injected directly into tumors and designed to stimulate an anti-tumor immune response.

The FDA's approval therefore provides patients with an additional treatment option while Replimune continues to generate evidence supporting its long-term benefit.

A Regulatory Test for Oncolytic Immunotherapy

The outcome of IGNYTE-3 could also have implications beyond Replimune.

Tudriqev represents the growing field of oncolytic immunotherapy, in which engineered viruses are used to attack tumor cells while activating the immune system.

If the Phase 3 trial confirms the clinical benefit seen in earlier research, it could strengthen confidence in this therapeutic approach and encourage further development of similar cancer treatments.

The case also demonstrates how accelerated approval can provide earlier access to innovative therapies while requiring manufacturers to continue generating stronger evidence after launch.

What Happens Next?

Replimune's immediate priorities are now both commercial and clinical.

The company must begin delivering Tudriqev to eligible patients while continuing the confirmatory Phase 3 program. The IGNYTE-3 results will be closely watched by the FDA, investors, physicians, and the broader oncology industry.

Current reporting indicates that results from the confirmatory Phase 3 study are expected around 2030, making the next several years an important period for determining Tudriqev's long-term regulatory and commercial trajectory.

Conclusion

Tudriqev's FDA accelerated approval represents a major achievement for Replimune, but it should not be viewed as the final chapter in the drug's regulatory story.

The Phase 3 IGNYTE-3 trial now carries the responsibility of confirming whether the clinical benefit observed in the earlier IGNYTE study can be demonstrated through stronger comparative evidence.

For Replimune, successful results could transform Tudriqev from a promising accelerated-approval therapy into a more firmly established treatment for immunotherapy-resistant melanoma. For patients, the trial could determine whether a new oncolytic immunotherapy becomes a durable part of the treatment landscape.

Until those results are available, Tudriqev's accelerated approval remains an important milestone—but full regulatory validation still depends on the evidence that comes next.